The renin inhibitor aliskiren attenuates high-glucose induced extracellular matrix synthesis and prevents apoptosis in cultured podocytes

Nephron - Experimental Nephrology

Volumn 118, Issue 3, 2011, Pages

  Phillips, Lynetta M ^a   Wang, Ying ^a   Dai, Tiane ^a   Feldman, David L ^b   LaPage, Janine ^a   Adler, Sharon G ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Aliskiren; Diabetic nephropathy; Extracellular matrix; High glucose; Podocytes; Renin inhibition

Indexed keywords

ALISKIREN; CASPASE 3; COLLAGEN TYPE 4; FIBRONECTIN; GELATINASE A; GELATINASE B; GLUCOSE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL SURVIVAL; EXTRACELLULAR MATRIX; MALE; MOUSE; NICK END LABELING; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION;

AMIDES; ANIMALS; APOPTOSIS; CELLS, CULTURED; COLLAGEN TYPE IV; DIABETIC NEPHROPATHIES; EXTRACELLULAR MATRIX; FIBRONECTINS; FUMARATES; GLUCOSE; MATRIX METALLOPROTEINASES; PODOCYTES; RENIN; RNA, MESSENGER;

EID: 78651259037     PISSN: 16602129     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000322242     Document Type: Article

References (45)

1. White KE, Bilous RW: Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant 2004; 19: 1437-1440. (Pubitemid 38786736)
2. Lupia E, Elliot SJ, Lenz O, Zheng F, Hattori M, Striker GE, Striker LJ: IGF-1 decreases collagen degradation in diabetic NOD mesangial cells. Diabetes 1999; 48: 1638-1644.
3. Meyer TW, Bennett PH, Nelson RG: Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 1999; 42: 1341-1344. (Pubitemid 29500971)
4. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000; 15: 1379-1383.
5. Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME, Wilkinson-Berka JL, Gilbert RE: Podocyte foot process broadening in experimental DN: Amelioration with renin-angiotensin blockade. Diabetologia 2001; 44: 878-882. (Pubitemid 32642461)
6. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Investigat 1997; 99: 342-348. (Pubitemid 27053474)
7. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MAF, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP: Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007; 13: 1349-1358. (Pubitemid 350073598)
8. Menini S, Iacobini C, Oddi G, Ricci G, Simonelli P, Fallucca S, Grattarola M, Pugliese F, Pesce C, Pugliese G: Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin- induced diabetes mellitus: Role in the development of diabetic glomerular disease. Diabetologia 2007; 50: 2591-2599. (Pubitemid 350060642)
9. Susztak K, Raff AC, Schiffer M, Bottinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-233. (Pubitemid 43343319)
10. Chuang PY, Yu Q, Fang W, Uribarri J, He JC: Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int 2007; 72: 965-976. (Pubitemid 47530572)
11. Bjorn SF, Bangstad HJ, Hanssen KF, Nyberg G, Walker JD, Viberti GC, Osterby R: Glomerular epithelial foot processes and filtration slits in IDDM patients. Diabetologia 1995; 38: 1197-1204.
12. Nakamura T, Ushiyama C, Shimada N, Sekizika K, Ebihara I, Hara M, Kiode H: Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy. Diabetes Care 2000; 23: 1168-1171. (Pubitemid 30616807)
13. Asanuma K, Campbel KN, Kim K, Faul C, Mundel P: Nuclear relocation of the nephrin and CD2AP-binding protein dendrin promotes apoptosis of podocytes. Proc Natl Acad Sci USA 2007; 104: 10134-10139. (Pubitemid 47175275)
14. Schiffer M, Bitzer M, Roberts ISD, Kopp JB, Dijke P, Mundel P, Bottinger EP: Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108: 807-816. (Pubitemid 32880291)
15. Mitu GM, Wang S, Hirschberg R: BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal 2007; 293:F1641-F1648. (Pubitemid 350086001)
16. Logan CM, Brinkkoetter PT, Krofft RD, Poppin JW, Shankland SJ: Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007; 72: 489-498. (Pubitemid 47237613)
17. Wu DT, Bitzer M, Ju W, Mundel P, Bottinger EP: TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol 2005; 16: 3211-3221. (Pubitemid 46179327)
18. Liebau MC, Lang D, Bohm J, Endlich N, Bek MJ, Witherden I, Mathieson PW, Saleem MA, Pavenstadt H, Fischer KG: Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol 2006; 290:F710-F719. (Pubitemid 43724974)
19. Yoo TH, Li JJ, Kim JJ, Jung DS, Kwak SJ, Ryu DR, Choi HY, Kim SJ, Kim HJ, Han SH, Lee JE, Han DS, Kang SW: Activation of the renin- angiotensin system within podocytes in diabetes. Kidney Int 2007; 71: 1019-1027. (Pubitemid 46741993)
20. Velez JCQ, Bland AM, Arthur JM, Raymond JR, Janech MG: Characterization of reninangiotensin system enzyme activities in cultured mouse podocytes. Am J Physiol Renal Physiol 2007; 293:F398-F407. (Pubitemid 47345041)
21. Bolick DT, Hatley ME, Srinivasan S, Hedrick CC, Nadler JL: Lisofylline, a novel antiinflammatory compound, protects mesangial cells from hyperglycemia and angiotensin IImediated extracellular matrix deposition. Endocrinology 2003; 144: 5227-5231. (Pubitemid 37476050)
22. Ikehara K, Hisaya T, Kuboki K, Inokuchi T: Role of kinase C-angiotensin II pathway for extracellular matrix production in cultured human mesangial cells exposed to high glucose levels. Diabetes Res Clin Pract 2003; 59: 25-30. (Pubitemid 35461906)
23. Kang SW, Natarajan R, Shahed A, Nast CC, LaPage J, Mundel P, Kashtan C, Adler SG: Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen α5(IV) in experimental diabetic nephropathy and glucose-stimulated podocytes. J Am Soc Nephrol 2003; 14: 3178-3187. (Pubitemid 37509293)
24. Kang SW, Adler SG, Nast CC, LaPage J, Gu J, Nader JL, Natarajan R: 12-Lipoxygenase is increased in glucose-stimulated mesangial cells and in experimental diabetic nephropathy. Kidney Int 2001; 59: 1354-1362. (Pubitemid 32281223)
25. Iglesias-De La Cruz MC, Ziyadeh FN, Isono M, Kouahou M, Han DC, Kalluri R, Mundel P, Chen S: Effects of high glucose and TGF-β 1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002; 62: 901-913. (Pubitemid 35316719)
26. Wang Y, Zhou J, Minto AW, Hack BK, Alexander JJ, Haas M, Li TC, Heilig CW, Quigg RJ: Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. Kidney Int 2006; 70: 882-891. (Pubitemid 44285965)
27. McLennan SV, Kelly DJ, Cox AJ, Cao Z, Lyons JG, Yue DK, Gilbert RE: Decreased matrix degradation in diabetic nephropathy: Effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002; 45: 268-275. (Pubitemid 34208390)
28. Morano S, Cipriani R, Santangelo C, Fallarino M, Carnovale A, Mandosi E, Gatti A, Sensi M, Di Mario U: Angiotensin blockade and matrix synthesis by glomerular epithelial cells in high glucose: A further experimental insight into the pathophysiology of diabetic nephropathy. Clin Ter 2008; 159: 151-154. (Pubitemid 352007547)
29. Imai K, Ohuchi E, Aoki T, Nomura H, Fujii Y, Sato H, Seiki M, Okada Y: Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res 1996; 56: 2707-2710.
30. Kitsiou PV, Tzinia AK, Stetler-Stevenson WG, Michael AF, Fan WW, Zhou B, Tsilibary C: Glucose-induced changes in integrins and matrix-related function in cultured human glomerular epithelial cells. Am J Physiol Renal Physiol 2003; 284:F671-F679. (Pubitemid 36336973)
31. McLennan SV, Martell SKY, Yue DK: Effects of mesangium glycalation on matrix metalloproteinase activities: Possible role in diabetic nephropathy. Diabetes 2002; 51: 2612-2618. (Pubitemid 34827414)
32. Bai Y, Wang L, Li Y, Liu S, Li J, Wang H, Huang H: High ambient glucose levels modulates the production of MMP9 and alpha5(IV) collagen by culture podocytes. Cell Physiol Biochem 2005; 17: 57-68.
33. Vempati P, Karagiannis ED, Popel AS: A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem 2007; 282: 37585-37596.
34. Sehgal I, Thompson TC: Novel regulation of type IV collagenase (matrix metalloproteinase- 9 and -2) activities by transforming growth factor-B1 in human prostate cancer cell lines. Mol Biol Cell 1999; 10: 407-416. (Pubitemid 29156481)
35. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE: Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50: 2398-2404. (Pubitemid 47512400)
36. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G: Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52: 130-136.
37. Rossing K, Jacobsen P, Pietraszek L, Parving HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy. Diabetes Care 2003; 28: 2268-2274. (Pubitemid 36993311)
38. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenburg NK: Aliskiren combined with losartan in type-2 diabetes and nephropathy. N Engl J Med 2008; 353: 2433-2446. (Pubitemid 351793017)
39. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen N, Rasetti V, Ruger H, Goschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum H, Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: 698-705. (Pubitemid 36976519)
40. Lods N, Ferrari P, Frey FJ, Kappeler A, Berthier C, Vogt B, Marti H: Angiotensinconverting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. J Am Soc Nephrol 2003; 14: 2861-2872. (Pubitemid 37305649)
41. Ziyadeh FN, Sharma K, Ericksen M, Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by HG is mediated by autocrine activation of TGF-beta. J Clin Invest 1994; 93: 536-542. (Pubitemid 24072793)
42. Ding G, Reddy K, Kapasi AA, Franki N, Gibbons N, Kasinath BS, Singhal PC: Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol 2002; 283:F173-F180. (Pubitemid 34680484)
43. Leehey DJ, Singh AK, Alavi N, Singh R: Role of angiotensin II in diabetic nephropathy. Kidney Int 2000; 58:S93-S98.
44. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen UL, Jerums G, Cooper ME: Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: Effects of ACE inhibition. Diabetes 1998; 47: 414-422. (Pubitemid 28104204)
45. Yao Q, Qian JQ, Lin XH, Lindholm B: Inhibition of the effect of high glucose on the expression of Smad in human peritoneal mesothelial cells. Int J Artif Organs 2004; 27: 828-834. (Pubitemid 40484594)